Author: Ken Dropiewski

Zynex Announces 117% Year over Year Order Growth and Increases Adjusted EBITDA Estimate

ENGLEWOOD, Colo., Jan. 12, 2021 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q4 2020. Thomas Sandgaard, CEO of Zynex said: “We concluded 2020 with strong orders and posted […]

Azin Parhizgar, Ph.D. Joins InnovHeart as Independent Member of the Board of Directors

NEWTON, Mass. and MILANO, ITALY, Jan. 12, 2021 /PRNewswire/ — InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of Mitral Regurgitation, announced today the appointment of successful serial entrepreneur and medical device executive Dr. Azin Parhizgar, Ph.D. as an Independent Member of the Board of Directors. Dr. Parhizgar […]

FineHeart Successfully Tests the Implantable, Wireless Transcutaneous Energy Transfer (TET) System for Powering Its ICOMS Heart Pump

A major step and a critical milestone achieved prior to First In Human clinical trials FineHeart’s TET is a system with no percutaneous driveline that transfers energy through the skin to charge the ICOMS pump battery TET is rapidly implantable (less than 15 mins) and will give patients autonomy The […]

Anura™: World’s first app allowing for contactless blood pressure measurement, without the need for cuffs or other wearables

The Affective AI-based app, contactlessly records and measures blood pressure and over ten other physiological and psychological indexes. TORONTO, Jan. 12, 2021 /PRNewswire/ — Toronto-based tech firm, NuraLogix, will be showcasing the groundbreaking app Anura™ at CES 2021. Originally debuted at CES Asia 2019, Anura™ is an Affective AI based app that allows contactless health […]

Optimize EP Emerges From Stealth Mode With Launch of CaRM Cardiac Device Data Management Platform

Digital Tool Automates Workflow Processes and Enhances Data Algorithms to Efficiently Improve Patient Care January 12th, 2021 STEUBENVILLE, OH / ACCESSWIRE / January 12, 2021 / Optimize EP, a digital health company focused on transforming cardiac care by improving the current state of cardiac data management, today emerged from stealth mode […]

Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials […]

Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure

Cardiovascular Publication Explores the Prespecified BETonMACE Analysis on Hospitalization for Heart Failure Following Acute Coronary Syndrome CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone and hospitalization for heart failure in patients following an acute […]

BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana

PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation. Westport, CT, Jan. 12, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an […]

Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates

Results Validate In Vivo Liver DNA Base Editing as a Once-and-Done Approach to Treat Coronary Heart Disease by Lowering of LDL Cholesterol and PCSK9 Protein Levels Company Selects VERVE-101 as Lead Program to Treat Heterozygous Familial Hypercholesterolemia CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, […]

Impulse Dynamics Closes $60 Million Financing

Funding to Accelerate Clinical and Product Development Pipelines, Commercialization of Optimizer Smart System for Heart Failure MARLTON, N.J.–(BUSINESS WIRE)–Impulse Dynamics, a company dedicated to helping healthcare providers improve the lives of people with heart failure, today announced the completion of a $60 million supplemental Series D crossover financing with new […]